United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $2,092,160.00 in Stock
United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $2,092,160.00 in Stock
United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the firm's stock in a transaction on Friday, January 13th. The shares were sold at an average price of $261.52, for a total transaction of $2,092,160.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $33,997.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
联合治疗公司(纳斯达克:UTHR-GET评级)首席执行官马丁·A·罗斯布拉特在1月13日(星期五)的一笔交易中出售了8,000股该公司股票。这些股票的平均价格为261.52美元,总成交金额为2,092,160.00美元。出售后,这位首席执行官现在拥有该公司130股,价值约33,997.60美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过这个环节.
United Therapeutics Trading Down 0.6 %
联合治疗公司股价下跌0.6%
United Therapeutics stock traded down $1.54 during trading hours on Wednesday, reaching $259.56. The stock had a trading volume of 286,221 shares, compared to its average volume of 401,356. The stock has a market cap of $11.83 billion, a PE ratio of 17.65, a PEG ratio of 1.54 and a beta of 0.62. United Therapeutics Co. has a 52 week low of $158.38 and a 52 week high of $283.09. The company has a debt-to-equity ratio of 0.18, a current ratio of 9.68 and a quick ratio of 9.39. The company has a fifty day simple moving average of $270.88 and a 200-day simple moving average of $240.79.
联合治疗公司的股票在周三的交易时间里下跌了1.5美元,达到259.56美元。该股成交量为286,221股,而其平均成交量为401,356股。该股市值为118.3亿美元,市盈率为17.65倍,市盈率为1.54倍,贝塔系数为0.62倍。联合治疗公司股价跌至158.38美元的52周低点和283.09美元的52周高点。该公司的债务权益比为0.18,流动比率为9.68,速动比率为9.39。该公司的50日简单移动均线切入位在270.88美元,200日简单移动均线切入位在240.79美元。
United Therapeutics (NASDAQ:UTHR – Get Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.57 by $1.34. The business had revenue of $516.00 million for the quarter, compared to analyst estimates of $492.92 million. United Therapeutics had a net margin of 38.03% and a return on equity of 16.63%. Analysts forecast that United Therapeutics Co. will post 16.63 EPS for the current fiscal year.
联合治疗公司(纳斯达克:UTHR-GET评级)上一次公布季度收益是在11月2日星期三。这家生物技术公司公布本季度每股收益(EPS)为4.91美元,超出分析师普遍预期的3.57美元,超出1.34美元。该业务本季度营收为5.16亿美元,而分析师预期为4.9292亿美元。联合治疗公司的净利润率为38.03%,股本回报率为16.63%。分析师预测,联合治疗公司本财年每股收益将达到16.63美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Institutional Investors Weigh In On United Therapeutics
机构投资者看好联合治疗公司
A number of large investors have recently added to or reduced their stakes in UTHR. Wellington Management Group LLP boosted its stake in shares of United Therapeutics by 73.7% during the 1st quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company's stock valued at $300,585,000 after purchasing an additional 710,668 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of United Therapeutics by 205.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 641,656 shares of the biotechnology company's stock valued at $151,200,000 after purchasing an additional 431,739 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of United Therapeutics by 1,011.5% during the 2nd quarter. Deutsche Bank AG now owns 196,876 shares of the biotechnology company's stock valued at $46,393,000 after purchasing an additional 179,163 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of United Therapeutics by 3.8% during the 3rd quarter. Vanguard Group Inc. now owns 4,411,616 shares of the biotechnology company's stock valued at $923,703,000 after purchasing an additional 163,542 shares in the last quarter. Finally, Farallon Capital Management LLC boosted its stake in shares of United Therapeutics by 40.0% during the 3rd quarter. Farallon Capital Management LLC now owns 549,673 shares of the biotechnology company's stock valued at $115,091,000 after purchasing an additional 156,977 shares in the last quarter. Institutional investors own 95.63% of the company's stock.
一些大型投资者最近增持或减持了UTHR的股份。惠灵顿管理集团LLP在第一季度将其在联合治疗公司的股份增加了73.7%。惠灵顿管理集团(Wellington Management Group LLP)现在拥有这家生物技术公司1,675,414股股票,价值300,585,000美元,上个季度又购买了710,668股。Assenagon Asset Management S.A.在第二季度增持了联合治疗公司的股份205.7%。Assenagon Asset Management S.A.现在持有这家生物技术公司641,656股股票,价值151,200,000美元,上个季度又购买了431,739股。德意志银行(Deutsche Bank AG)在第二季度增持了联合治疗公司1,011.5%的股份。德意志银行(Deutsche Bank AG)现在持有这家生物技术公司196,876股股票,价值46,393,000美元,上个季度又购买了179,163股。先锋集团(Vanguard Group Inc.)在第三季度增持联合治疗公司3.8%的股份。先锋集团(Vanguard Group Inc.)目前持有这家生物技术公司4,411,616股股票,价值923,703,000美元,上个季度又购买了163,542股。最后,Farallon Capital Management LLC在第三季度将其在联合治疗公司的股份增加了40.0%。Farallon Capital Management LLC现在拥有这家生物技术公司549,673股股票,价值115,091,000美元,上个季度又购买了156,977股。机构投资者持有该公司95.63%的股份。
About United Therapeutics
关于联合治疗公司
(Get Rating)
(获取评级)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
联合治疗公司是一家生物技术公司,致力于产品的开发和商业化,以满足美国和国际上慢性和危及生命的疾病患者未得到满足的医疗需求。其商业疗法包括用于治疗肺动脉高压(PAH)患者的Remodlin,以减轻运动相关症状;TYVASO,一种前列环素类似物Treprostinil的吸入制剂,用于增强PAH患者的运动能力;Treprostinil的片剂Orenitram,用于增强PAH患者的运动能力;Unitusin,用于治疗高危神经母细胞瘤;以及AdCirca,口服PDE-5抑制剂,用于增强PAH患者的运动能力。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
- Can Alaska Air Continue Soaring Above The Airline Industry?
- 免费获取StockNews.com关于联合治疗(UTHR)的研究报告
- 如新控股股票与沃伦·巴菲特有什么关系?
- J.B.亨特买房,物流公司成为焦点
- 英特尔股票是否即将突破?
- 人们对百事可乐的新苏打水不感兴趣,这有什么关系吗?
- 阿拉斯加航空能否继续在航空业之上高歌猛进?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受联合治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对联合治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。